Adipose Stromal Vascular Fraction Dosing for Better Stem Cell Distribution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pulmonary disorders, neurodegenerative disorders, brain injury, psychiatric disorders, metabolic disorders, and pain are either insufficient or cause undesirable adverse side effects, highlighting the need for more effective and safer therapeutic methods.
Innovation Solution
Intravenous administration of a stromal vascular fraction derived from adipose tissue, processed without enzymes or sonication probes, following specific dosing schedules to improve systemic distribution and reduce lung congregation of stem cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If stem cells are administered intravenously to treat disorders, then therapeutic benefits are provided, but stem cells tend to congregate in the lungs reducing effectiveness for other disorders
Solution Approach 1:
The patent administers a priming dose of stem cells before the therapeutic dose to prepare the vascular system. This preliminary action modifies the vascular environment to prevent subsequent congregation of therapeutic stem cells in the lungs, enabling better systemic distribution and targeting of intended organs.
Solution Approach 2:
The patent uses an intermediary substance (such as albumin or dextran) co-administered with stem cells to modify their circulation behavior. This intermediary acts as a mediator that prevents stem cell aggregation in pulmonary capillaries while maintaining their therapeutic function in target organs.
2Ease of manufacture
If enzymes or sonication probes are used to process adipose tissue, then stromal vascular fraction is obtained, but risk of contamination increases
Solution Approach 1:
The patent extracts and removes enzymes and sonication probes from the adipose tissue processing procedure. Instead, it uses mechanical agitation and filtration methods that achieve sufficient stromal vascular fraction separation without introducing contamination risks associated with biological enzymes or probe-based sonication.
Solution Approach 2:
The patent employs disposable sterile filters and simple mechanical mixing devices that can be discarded after single use. This eliminates the need for complex sterilization procedures required for reusable enzymes and sonication probes, thereby reducing contamination risk while maintaining processing effectiveness.
3Reliability
If high concentration of stem cells is administered, then therapeutic outcomes are enhanced, but lung congregation is worsened
Solution Approach 1:
The patent administers a priming dose of stem cells at lower concentration before the high-concentration therapeutic dose. This preliminary action prepares the vascular system to handle the subsequent high-concentration infusion, preventing lung congestion while maintaining therapeutic efficacy.
Solution Approach 2:
The patent divides stem cell administration into periodic doses administered over multiple days or sessions. This periodic approach allows the vascular system to process and distribute stem cells more effectively, reducing acute lung congregation while achieving cumulative therapeutic benefits.
Data Source
AI summary
The invention provides methods and compositions utilizing stromal vascular fraction derived from adipose tissue to treat various medical disorders, such as pulmonary disorders, neurodegenerative disorders, brain injury, psychiatric disorders, metabolic disorders, and pain.